WA
AUTL

Waverly Advisors’s Autolus Therapeutics AUTL Stock Holding History

Waverly Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43K Hold
26,870
– – ﹤0.01% 1709
2026
Q1 		$37.1K Buy
+26,870
New +$40.8K ﹤0.01% 1572

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Waverly Advisors's AUTL Position: Q2 2026 in Review

Waverly Advisors held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 26,870 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Waverly Advisors first reported a position in AUTL in Q1 2026 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Waverly Advisors held 26,870 shares of Autolus Therapeutics worth $43K as of Q2 2026.
  • Waverly Advisors left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1709 holding.
  • Waverly Advisors first reported a position in Autolus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.